William Blair Issues Negative Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Stock analysts at William Blair dropped their Q2 2025 earnings estimates for shares of CRISPR Therapeutics in a research note issued on Wednesday, May 7th. William Blair analyst S. Corwin now anticipates that the company will earn ($1.10) per share for the quarter, down from their prior forecast of ($1.01). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. William Blair also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.85) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($3.16) EPS.

CRSP has been the topic of a number of other research reports. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and raised their price objective for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Royal Bank of Canada dropped their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research report on Wednesday, February 12th. Finally, Chardan Capital dropped their target price on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded up $1.97 during midday trading on Friday, hitting $37.59. The company's stock had a trading volume of 1,959,320 shares, compared to its average volume of 1,670,582. The firm has a market cap of $3.25 billion, a P/E ratio of -8.60 and a beta of 1.88. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The firm's 50 day moving average is $38.15 and its 200-day moving average is $42.71.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter in the previous year, the business earned ($1.43) EPS. The firm's quarterly revenue was up 71.6% on a year-over-year basis.

Insider Activity

In related news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. The trade was a 9.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John Greene purchased 7,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 26th. The stock was bought at an average cost of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now directly owns 7,000 shares of the company's stock, valued at approximately $313,950. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Large investors have recently modified their holdings of the stock. Costello Asset Management INC bought a new stake in CRISPR Therapeutics during the 1st quarter worth approximately $27,000. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter worth $30,000. Ameriflex Group Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $36,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $39,000. Finally, Western Pacific Wealth Management LP raised its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares during the period. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.